Xerostomia (dry mouth) therapeutics market is projected to grow at a considerable CAGR of 7% during the forecast period. As per the American Dental Association, the rate of prevalence of xerostomia in the general population ranges from 0.9% to 64.8%. Severance of xerostomia leads to a critical impact on the patient’s health and quality life as it causes oral discomfort to the patient. The rise in the prevalence of Sjogren’s syndrome along with an increase in the consumption of medications is a major factor to drive the growth of the global xerostomia therapeutics market. As per the Association, the prevalence of xerostomia is considered 100% in patients with Sjogren’s syndrome or patients who have undergone radiation therapy for head and neck cancer.
Get Free Sample link @ https://www.omrglobal.com/request-sample/xerostomia-dry-mouth-therapeutics-market
According to the Rare Genomics Institute, Sjogren’s syndrome is the third most common autoimmune disorder, behind rheumatoid arthritis and systemic lupus erythematosus. It is the common disorder amongst females that account for 90% of all Sjogren Syndrome cases. This syndrome affects individuals between the ages of 40 to 60. The US witnessed 0.2 million to 3 million cases related to Sjogren’s syndrome per year.
A full report of Global Xerostomia (Dry Mouth) Therapeutics Market available @ https://www.omrglobal.com/industry-reports/xerostomia-dry-mouth-therapeutics-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
Global Xerostomia Therapeutics Market by Product Type
- Artificial Saliva
- Dentifrices
- Drugs
- Salivary Stimulants
- Saliva Substitutes
- Salivary Pen
Global Xerostomia Therapeutics Market by Type
- Prescribed Drugs
- OTC Drugs
Regional Analysis
- North America
- US
- Canada
- Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- Rest of the World
Company Profiles
- 3M Co.
- Acacia Pharma Group Plc
- Bausch Health Companies, Inc.
- Colgate-Palmolive Co.
- Eisai, Inc.
- EUSA Pharma NP
- Forward Science
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals Plc
- Lupin Pharmaceuticals, Inc.
- Mission Pharmacal Co.
- OraHealth Corp. (OraCoat)
- OraPharma, Inc.
- Parnell Pharmaceuticals, Inc.
- Pfizer, Inc.
- Pharmascience, Inc. (Pendopharm)
- Quest Products, LLC (OraCoat)
- Saliwell, Ltd.
- Synedgen
- Sun Pharmaceuticals Industries, Ltd.
The Report Covers
- Market value data analysis of 2018 and forecast to 2025.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global xerostomia therapeutics market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/xerostomia-dry-mouth-therapeutics-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
